Immediate Impact
17 standout
Citing Papers
Neoadjuvant Chemoimmunotherapy for NSCLC
2024 Standout
Non-small-cell lung cancer
2024 Standout
Works of A. Bardet being referenced
LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| A. Bardet | 67 | 18 | 2 | 45 | 19 | 114 | |
| Ioanna Nixon | 55 | 22 | 1 | 44 | 21 | 173 | |
| Ashlyn S. Everett | 29 | 17 | 41 | 16 | 98 | ||
| Franel Le Grange | 90 | 15 | 48 | 16 | 139 | ||
| Gabriele Infante | 59 | 10 | 76 | 26 | 177 | ||
| Maiwand Ahmadsei | 68 | 35 | 35 | 23 | 133 | ||
| Ying Sun | 41 | 33 | 26 | 19 | 171 | ||
| Lalit Mohan Sharma | 57 | 15 | 32 | 25 | 135 | ||
| Isao Numata | 130 | 12 | 43 | 19 | 227 | ||
| Tatiana Conrad | 110 | 23 | 46 | 24 | 136 | ||
| Lauris Gastaud | 50 | 12 | 71 | 19 | 201 |
All Works
Loading papers...